49 A recent study has highlighted the transformative potential of metal-organic frameworks (MOFs) in advancing cancer treatment. MOFs, constructed from organic ligands and metal ions, offer a flexible and highly tunable platform for therapeutic innovation, particularly in light-mediated therapies such as photodynamic therapy (PDT) and photothermal therapy (PTT). The findings were published in the journal Coordination Chemistry Reviews. Phototherapy, which utilises light-activated agents, is increasingly viewed as a viable alternative to traditional treatments like chemotherapy and surgery. These methods often cause significant side effects and are less effective in targeting tumours. PDT generates reactive oxygen species to destroy cancer cells, while PTT uses heat to induce tumour cell death. MOFs have emerged as game changers due to their ability to combine and enhance these therapies. The research emphasises the advantages of MOFs, including their porous structures that prevent material aggregation, thereby increasing therapeutic efficacy. These frameworks can act as carriers for therapeutic agents or serve directly as photothermal or photosensitising agents. For instance, MOFs can be modified to release specific drugs in response to the acidic environments of tumours, ensuring precision targeting with minimal impact on healthy tissues. Moreover, these frameworks are pivotal in overcoming challenges associated with traditional phototherapies, such as poor tissue penetration and dependency on oxygen. Scientists are exploring innovations like two-photon activation and integration with other therapeutic modes such as chemotherapy and immunotherapy. This approach enables multi-modal treatments that not only attack tumours more effectively but also reduce the likelihood of cancer resistance. The versatility of MOFs extends to imaging, offering guidance during therapy. Functionalised MOFs with imaging agents enable clinicians to monitor the treatment process in real-time, providing insights into drug delivery and therapeutic outcomes. Researchers have already demonstrated MOFs’ success in animal models, with promising results in reducing tumour growth and preventing metastasis. Despite their potential, MOFs are not without challenges. Key issues include ensuring their complete biodegradability and biocompatibility. Addressing these concerns is vital to minimising long-term toxicity and ensuring their safe clearance from the body. The authors of the study advocate further exploration into their pharmacokinetics and integration with minimally invasive delivery methods to maximise their clinical utility. As MOFs continue to evolve, their role in cancer treatment is expected to expand significantly. Their ability to merge therapeutic and diagnostic functions, coupled with their adaptability for multi-modal approaches, positions them as a frontier technology in oncology. While these frameworks are not yet ready for widespread clinical application, their rapid development suggests they could redefine cancer treatment paradigms in the near future.